Admission high-sensitivity cardiac troponin levels as a prognostic indicator for in-hospital mortality rates in the elderly and very elderly COVID-19 patients.


Journal

Archives of gerontology and geriatrics
ISSN: 1872-6976
Titre abrégé: Arch Gerontol Geriatr
Pays: Netherlands
ID NLM: 8214379

Informations de publication

Date de publication:
01 2023
Historique:
received: 05 07 2022
revised: 13 09 2022
accepted: 18 09 2022
pubmed: 27 9 2022
medline: 19 11 2022
entrez: 26 9 2022
Statut: ppublish

Résumé

Elevation of cardiac troponin (cTn) is associated with the worst prognosis not only in cardiovascular disease but also in non-cardiovascular disease. The aim of this study is to verify if cTn has a prognostic role in elderly and very elderly coronavirus disease 2019 (COVID-19) patients. This study enrolled consecutive COVID-19 elderly patients hospitalized at INRCA hospital, with available admission high sensitivity cardiac troponin T (HS-cTnT) level. Patients were divided into three groups based on HS-cTnT level: group A (Hs-cTnT ≤ 40 pg/ml), group B (Hs-cTnT 41-100 pg/ml), and group C (Hs-cTnT ≥ 101 pg/ml). The correlation between HS-cTnT levels and mortality rates was analyzed. 461 patients (mean age 86 years; 59% female) were divided into group A (261 patients), group B (129 patients), and group C (71 patients). Group C resulted significantly older, more affected by heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and dementia, and with higher levels of creatinine, C-reactive protein, pro-calcitonin, interleukin-6, ferritin, NT-proBNP, D-dimer then group A and group B. Mortality rate increased significantly across groups (group A: 18.4%; group B: 36.4%; group C: 62.0%; p<0.001). Group C had a significant increase in mortality risk compared to group A, both univariate analysis (HR 3.78) and multivariate analysis (model 2 HR 3.10; model 3 HR 3.59; model 4 HR 1.72). HS-cTnT has demonstrated a prognostic role in elderly and very elderly COVID-19 patients. HS-cTnT is a simple and inexpensive laboratory exam that gives clinicians important information on mortality risk stratification.

Sections du résumé

BACKGROUND
Elevation of cardiac troponin (cTn) is associated with the worst prognosis not only in cardiovascular disease but also in non-cardiovascular disease. The aim of this study is to verify if cTn has a prognostic role in elderly and very elderly coronavirus disease 2019 (COVID-19) patients.
METHODS
This study enrolled consecutive COVID-19 elderly patients hospitalized at INRCA hospital, with available admission high sensitivity cardiac troponin T (HS-cTnT) level. Patients were divided into three groups based on HS-cTnT level: group A (Hs-cTnT ≤ 40 pg/ml), group B (Hs-cTnT 41-100 pg/ml), and group C (Hs-cTnT ≥ 101 pg/ml). The correlation between HS-cTnT levels and mortality rates was analyzed.
RESULTS
461 patients (mean age 86 years; 59% female) were divided into group A (261 patients), group B (129 patients), and group C (71 patients). Group C resulted significantly older, more affected by heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and dementia, and with higher levels of creatinine, C-reactive protein, pro-calcitonin, interleukin-6, ferritin, NT-proBNP, D-dimer then group A and group B. Mortality rate increased significantly across groups (group A: 18.4%; group B: 36.4%; group C: 62.0%; p<0.001). Group C had a significant increase in mortality risk compared to group A, both univariate analysis (HR 3.78) and multivariate analysis (model 2 HR 3.10; model 3 HR 3.59; model 4 HR 1.72).
CONCLUSION
HS-cTnT has demonstrated a prognostic role in elderly and very elderly COVID-19 patients. HS-cTnT is a simple and inexpensive laboratory exam that gives clinicians important information on mortality risk stratification.

Identifiants

pubmed: 36156408
pii: S0167-4943(22)00209-6
doi: 10.1016/j.archger.2022.104822
pmc: PMC9484855
pii:
doi:

Substances chimiques

Biomarkers 0
Natriuretic Peptide, Brain 114471-18-0
Troponin T 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104822

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None to declare

Références

Int J Mol Sci. 2021 Nov 21;22(22):
pubmed: 34830421
Clin Interv Aging. 2018 Dec 31;14:81-90
pubmed: 30643397
JACC Cardiovasc Interv. 2012 Sep;5(9):906-16
pubmed: 22995877
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Aging (Albany NY). 2020 Sep 29;12(18):18778-18789
pubmed: 32991323
Eur J Intern Med. 2021 Apr;86:48-53
pubmed: 33353803
Adv Exp Med Biol. 2020;1216:55-64
pubmed: 31894547
Front Immunol. 2020 Oct 27;11:579220
pubmed: 33193377
Int J Cardiol Heart Vasc. 2019 Mar 08;22:187-191
pubmed: 30963093
Am J Emerg Med. 2020 Jul;38(7):1504-1507
pubmed: 32317203
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Ann Clin Biochem. 2020 May;57(3):202-205
pubmed: 32255359
Int J Cardiol Heart Vasc. 2020 Jun 03;29:100557
pubmed: 32550259
Nat Rev Endocrinol. 2018 Oct;14(10):576-590
pubmed: 30046148
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
J Card Fail. 2020 Jun;26(6):470-475
pubmed: 32315733
Am J Epidemiol. 2019 Dec 31;188(12):2146-2155
pubmed: 31063194
J Geriatr Cardiol. 2021 May 28;18(5):338-345
pubmed: 34157060
Int J Cardiol Heart Vasc. 2020 Sep 09;31:100629
pubmed: 32964099
J Am Coll Cardiol. 2017 Aug 1;70(5):558-568
pubmed: 28750699
Ageing Res Rev. 2019 Dec;56:100980
pubmed: 31726228
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Am Coll Cardiol. 2020 Sep 29;76(13):1577-1594
pubmed: 32972536
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
JAMA Cardiol. 2020 Nov 01;5(11):1274-1280
pubmed: 32845276
J Am Coll Cardiol. 2020 Sep 8;76(10):1244-1258
pubmed: 32652195
Eur J Clin Invest. 2021 Jun;51(6):e13532
pubmed: 33660278
J Clin Med. 2021 Apr 07;10(8):
pubmed: 33916917
Mech Ageing Dev. 2012 May;133(5):300-5
pubmed: 22446505
Age Ageing. 2021 Nov 10;50(6):1979-1987
pubmed: 34254997
CJC Open. 2020 Jul 25;3(3):248-255
pubmed: 33778441

Auteurs

Alessio Menditto (A)

Cardiology Unit, IRCCS INRCA, Ancona, Italy. Electronic address: a.menditto@INRCA.it.

Olga Protic (O)

Cardiology Unit, IRCCS INRCA, Ancona, Italy.

Mirko Di Rosa (M)

Unit of Geriatric Pharmacoepidemiology and Biostatistics, IRCCS INRCA, Ancona, Italy.

Anna Rita Bonfigli (AR)

Scientific Direction, IRCCS INRCA, Ancona, Italy.

Fabrizia Lattanzio (F)

Scientific Direction, IRCCS INRCA, Ancona, Italy.

Roberto Antonicelli (R)

Cardiology Unit, IRCCS INRCA, Ancona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH